Patent claims

- 1. The use of N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C₈₋₁₈)arylsulfonamides, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, in the preparation of a medicament for the treatment of a disorder mediated by the action of steroid sulfatase.
- 2. The use of claim 1, wherein an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C₈₋₁₈)arylsulfonamide is a compound of formula

$$\begin{array}{c|c} R_2 & \\ \hline \\ R_3 & \\ \hline \\ R_4 & \\ \end{array}$$

10

15

20

5

wherein

 R_1 is unsubstituted (C_{8-18})aryl, or (C_{8-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-8})alkyl,

 R_2 is (C_{1-12}) alkoxycarbonyl, (C_{1-8}) alkylcarbonyl, (C_{3-6}) cycloalkyl (C_{1-6}) alkylcarbonyl or unsubstituted (C_{8-18}) aryl, or (C_{8-18}) aryl substituted by aminocarbonyl, halogen or halo (C_{1-6}) alkyl, and

EITHER

- R₃, R₄ and R₅ are hydrogen

OR

- R_3 and R_5 together are (C1-4)alkylene and R_4 is hydrogen.

3. A compound of formula

$$\begin{array}{c|c} R_{2} & & & \\ R_{3} & & & \\ R_{4} & & & \\ \end{array}$$

wherein

- 25 -
- R_1 is unsubstituted (C_{8-18})aryl, or (C_{8-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-8})alkyl,
- R₂` is (C₁₋₁₂)alkoxycarbonyl, (C₁₋₈)alkylcarbonyl, (C₃₋₈)cycloalkyl(C₁₋₈)alkylcarbonyl or unsubstituted (C₈₋₁₈)aryl, or (C₈₋₁₈)aryl substituted by aminocarbonyl, halogen or halo(C₁₋₈)alkyl,

 R_3 and R_5 together are (C_{1-4})alkylene, and R_4 is hydrogen.

4. A compound of formula

10

15

20

25

5

wherein

- R_1 is unsubstituted (C_{8-18})aryl, or (C_{8-18})aryl substituted by aminocarbonyl, halogen or halo(C_{1-8})alkyl, and
- R_2 is (C_{1-12}) alkoxycarbonyl, (C_{3-8}) cycloalkyl (C_{1-8}) alkylcarbonyl, unsubstituted (C_{8-18}) aryl, or (C_{8-18}) aryl substituted by aminocarbonyl, halogen or halo (C_{1-8}) alkyl.
- 5. A compound of formula II, which is

N-(3-thia-5,11-diaza-tricyclo[6.2.1.0*2,6*]undeca-2(6),4-dien-4-yl)-benzenesulfonamide, or a compound of formula III, which is selected from the group consisting of

- 2-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
 - 2-[2-(2,3-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yi]-4-trifluoromethyl-benzamide,
 - 2-[2-(3,5-Dichloro-benzenesulfonylamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]-4-trifluoromethyl-benzamide,
 - 2-(3,5-Bis-trifluoromethyl-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
 - 2-(2,3-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester,
- 2-(3,5-Dichloro-benzenesulfonamino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5carboxylic acid tert-butyl ester, and

- N-[5-(2-Cyclopentyl-acetyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-yl]-3,5-bis-trifluoro-methyl-benzenesulfonamide.
- 6. A compound according to any one of claims 4 or 5 of formula

5


- 7. A compound of any one of claims 3 to 6 in the form of a salt.
- 8. A compound of any one of claims 3 to 7 for use as a pharmaceutical.

10

- 9. A pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound of any one of claims 3 to 7 in association with at least one pharmaceutically acceptable excipient.
- 10. A method of treating disorders mediated by the action of steroid sulfatase comprising administering a therapeutically effective amount of an N-(4,5,6,7-tetrahydro-thiazolo-[5,4-c]pyridin-2-yl)-(C₈₋₁₈)arylsulfonamide, wherein the nitrogen atom of the pyridine is substituted, and wherein the pyridine ring is optionally bridged, to a subject in need of such treatment.

20

11. A compound of formula



wherein X has the meaning of R_2 " in claim 4, or a compound of formula

WO 2004/043968

PCT/EP2003/012707

- 27 -

wherein X has the meaning of R_2 as defined in claim 3, or a compound of formula

5 wherein R_1 is as defined in claim 2.